Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Leveraging the molecular biology of gastrointestinal cancers for optimal benefit from immunotherapeutic approaches

Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer)

Date

03 Dec 2023

Session

Leveraging the molecular biology of gastrointestinal cancers for optimal benefit from immunotherapeutic approaches

Topics

Clinical Research;  Cancer Biology;  Cytotoxic Therapy;  Tumour Immunology;  Translational Research;  Molecular Oncology;  Immunotherapy

Tumour Site

Oesophageal Cancer;  Non-Small Cell Lung Cancer;  Head and Neck Cancers

Presenters

Brian Henick

Authors

B.S. Henick

Author affiliations

  • Medicine, Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, 10032 - New York/US

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.